drugset / Trial / NCT06353529

Postop Pain Management in Pituitary Tumour Patients

NCT06353529 ↗

Phase 4 Recruiting 108 enrolled Hamilton Health Sciences Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the benefit of using an additional nerve block during minimally invasive pituitary surgery, to improve pain management after surgery. The medication (Bupivacaine) or a placebo (saline) will be injected during surgery and patients will be asked about their level of pain at multiple time points in the first 24 hours following surgery. Some patients will be randomized to a third, sham group that do not receive any additional injection. The aim is to improve patient outcomes and reduce the need for pain medication after surgery.

Timeline

Start
2024-11-25
Primary completion
2026-04
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 0.5 % Other
Background Epinephrine Other / unclassified — Other

Indications